Open access
Jul 2026
In silico high-throughput screening system for INMT activators in prostate cancer therapy
DMPP-4M represents a promising INMT-targeted therapeutic agent, offering an AR-independent strategy for CRPC treatment, and subsequent structural optimization and in vivo experimental validation are required to advance its clinical translation potential.
Haoyuan Zheng, Shi-Long Cao, Zhuolin Kong et al.
· Frontiers in Pharmacology · 0 citations